The presence of non-responders to GLP-1R therapy continues to complicate treatment outcomes, underscoring the need for a deeper understanding of individual variability in response [117,118]
They might not be suitable for everyone, and its important to consider any potential adverse effects or combinations with other medications
[1] [6] The proposed mechanisms linking these therapies to gallbladder complications include altered gallbladder motility and bile composition changes
April 2, 2025: Lawsuits Against Eli Lillys Trulicity Increase in March There are now 1,685 active lawsuits pending against Trulicitys maker Novo Nordisk and other GLP-1 manufacturers
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: a meta-analysis and meta-regression
Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association
